Nucleic acid-based micelle incorporated with USE1-silencing siRNA for lung cancer therapy
발표자
()
초록
내용
UBA6-specific E2 conjugation enzyme 1 (USE1) was frequently overexpressed in lung cancer patients. We aimed to develop USE1-targeted therapeutic agents based on RNA interference (RNAi). In this study, we introduce a lipid-modified DNA carrier to increase the cell permeability of siRNA targeting of USE1. The U4Ts aggregate to form micelles, and the USE1-silencing siRNA-incorporated soft spherical nucleic acid aggregate (siSNA) can be created simply through base-pairing with siRNA. Treatment with siSNA was effective in suppressing tumor growth in vivo as well as cell proliferation, migration, and invasion of lung cancer cells. Furthermore, siSNA inhibited tumor cell growth by inducing cell cycle arrest in the G1 phase and apoptosis. Collectively, these results suggest that siSNA could be applied to the clinical application of RNAi-based therapeutics for lung cancer treatment.